Metropolitan Life Insurance Company (MetLife)’s Sana Biotechnology SANA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,125	Closed	-$51.3K	–	1726
2024 Q1	$51.3K	Hold	5,125	–	–	﹤0.01%	1394
2023 Q4	$20.9K	Hold	5,125	–	–	﹤0.01%	1906
2023 Q3	$19.8K	Hold	5,125	–	–	﹤0.01%	1906
2023 Q2	$30.5K	Buy	5,125 +1,907	+59%	+$11K	﹤0.01%	1703
2023 Q1	$10.5K	Sell	3,218 -2,525	-44%	-$10.1K	﹤0.01%	2139
2022 Q4	$22.7K	Hold	5,743	–	–	﹤0.01%	1946
2022 Q3	$34.5K	Hold	5,743	–	–	﹤0.01%	1714
2022 Q2	$36.9K	Hold	5,743	–	–	﹤0.01%	1687
2022 Q1	$47.4K	Sell	5,743 -17,543	-75%	-$142K	﹤0.01%	1632
2021 Q4	$360K	Hold	23,286	–	–	﹤0.01%	1627
2021 Q3	$524K	Buy	23,286 +14,416	+163%	+$303K	0.01%	1429
2021 Q2	$174K	Buy	8,870 +7,325	+474%	+$166K	﹤0.01%	2249
2021 Q1	$51.7K	Buy	+1,545	New	+$50.3K	﹤0.01%	2534

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SANA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Sana Biotechnology (SANA) in Q2 2024, closing a stake of 5,125 shares — an estimated $51.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SANA in Q1 2021 and held it in 13 quarters. The position peaked at $524K in Q3 2021. 147 funds tracked by Wall St. Rank hold SANA as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Sana Biotechnology position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 5,125 Sana Biotechnology shares in Q2 2024, an estimated $51.3K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Sana Biotechnology in Q1 2021 and held it in 13 quarters.
Metropolitan Life Insurance Company (MetLife)'s Sana Biotechnology position peaked at $524K in Q3 2021.
147 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.